Identification of key biomarkers of endothelial dysfunction in hypertension with carotid atherosclerosis based on

Yimin Wang1, Xinyang Shou2, Yuteng Wu2

  • 1The Third Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou, Zhejiang, 310005, China.

Heliyon
|July 10, 2024
PubMed

Insights

Two key genes, CCR1 and NCKAP1L, involved in immune responses, were identified as crucial in carotid atherosclerosis (CAS) development and endothelial dysfunction in hypertensive patients.

Area of Science:

  • Cardiovascular Biology
  • Genomics
  • Immunology

Background:

  • Endothelial dysfunction precedes carotid atherosclerosis (CAS) in hypertensive patients.
  • Identifying hub genes is crucial for understanding CAS pathogenesis.
  • This study focuses on uncovering key genes in endothelial dysfunction related to CAS.

Purpose of the Study:

  • To identify hub genes associated with endothelial dysfunction in carotid atherosclerosis (CAS).
  • To elucidate the pathological mechanisms underlying CAS progression in hypertension.
  • To validate potential therapeutic targets for CAS.

Main Methods:

  • Gene expression profiles from GSE43292 dataset were analyzed.
  • Weighted gene correlation network analysis (WGCNA) and LASSO regression identified hub genes.
  • Gene Ontology (GO) and KEGG pathway analyses explored biological functions.
  • In vitro experiments validated hub gene expression in human umbilical vein endothelial cells (HUVECs).

Main Results:

  • 161 differentially expressed genes were identified in CAS plaques.
  • The gray60 module from WGCNA was significantly associated with clinical features.
  • Immune response pathways were highlighted by GO and KEGG analyses.
  • Two hub genes, CCR1 and NCKAP1L, were identified via LASSO regression.
  • mRNA expression of CCR1 and NCKAP1L increased in ox-LDL treated HUVECs.

Conclusions:

  • Hub genes related to immune responses play a role in CAS development.
  • CCR1 and NCKAP1L are identified as key hub genes in endothelial dysfunction.
  • These genes represent potential therapeutic targets for CAS in hypertensive patients.
Abstract